Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Wake Forest School of Medicine.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Wake Forest School of Medicine
ClinicalTrials.gov Identifier:
NCT00696449
First received: June 9, 2008
Last updated: June 10, 2008
Last verified: June 2008

June 9, 2008
June 10, 2008
June 2006
May 2007   (final data collection date for primary outcome measure)
Percent change from baseline in total lesions counts [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00696449 on ClinicalTrials.gov Archive Site
Global Assessment of improvement from baseline. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

The purpose of this research study is to see how well the drug works for subjects who have acne. Adapalene 0.1% (Differin) will be used in this study to treat your acne. Differin is approved by the Food and Drug Administration (FDA) to treat acne.

Not Provided
Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Acne Vulgaris
  • Drug: Adapalene

    Subjects will treat the face once daily in the evening.

    This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.

    Other Name: Differin® Gel, 0.1%
  • Drug: Adapalene

    Subjects will treat the face once daily in the evening

    This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.

  • Drug: Adapalene

    Subjects will treat the face once daily in the evening

    n this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.

  • Drug: Adapalene

    Subjects will treat the face once daily in the evening

    This group is considered to be the "standard of care" arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.

  • Experimental: 1
    This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
    Intervention: Drug: Adapalene
  • Experimental: 2
    This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
    Intervention: Drug: Adapalene
  • Experimental: 3
    In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
    Intervention: Drug: Adapalene
  • Experimental: 4
    This group is considered to be the "standard of care" arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.
    Intervention: Drug: Adapalene
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
80
October 2008
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female Subjects of any race, aged 13 to 18 years inclusive,
  • Subjects with a diagnosis of moderate to severe Acne vulgaris, measured by lesion counts of a minimum of 15 and a maximum of 50 inflammatory lesions (papules and pustules) on the face, AND a minimum of 30 and a maximum of 125 total lesions. Subjects with nodules may participate in the study.
  • Female Subjects of childbearing potential must have a negative urine pregnancy test (UPT).
  • Female Subjects of childbearing potential must practice a highly effective method of contraception during the study
  • Subjects (and parent/guardian if Subject is under 18 years of age) must be willing and capable of following study instructions to the extent and degree required by the protocol;
  • Subjects able to follow study instructions and likely to complete all required visits;
  • Subjects/Representative signs the Informed Consent prior to any study procedures. Subjects under the age of 18 must have one parent or guardian read and sign the Informed Assent Form prior to receiving study treatment but the parent(s) or guardian is not required to attend the follow-up visits unless requested;
  • Subject must be willing to be photographed and sign a release form allowing photographs to be used.

Exclusion Criteria:

  • Female Subjects who are pregnant, nursing or planning a pregnancy during the study,
  • Subjects with a condition or who are in a situation which, in the Investigator's opinion, may put the Subject at risk, may confound the study results, or may interfere with the Subject's participation in the study,
  • Subjects with known allergy to one of the components of the test products,
  • Subjects who have participated in another investigational drug or device research study within 30 days of enrolment, Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or or severe acne requiring more than topical treatment (e.g. oral isotretinoin);
  • Subjects with a beard or other facial hair that might interfere with study assessments;
  • Subjects with underlying diseases or other dermatological conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea;
  • Subjects who are at risk in terms of precautions, warnings, and contra-indication (see package insert for Differin Gel, 0.1%);
  • Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.);
  • Subjects with a known history of drug and/or alcohol abuse.
Both
13 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00696449
00000406, 31219
No
Steve Feldman, MD PhD, Wake Forest University Health Sciences
Wake Forest School of Medicine
Not Provided
Principal Investigator: Steve Feldman, MD, PhD Wake Forest School of Medicine
Wake Forest School of Medicine
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP